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Abstract: The histone deacetylase inhibitor N1-(ferrocenyl)-N8-hydroxyoctanediamide (JAHA)
down-regulates extracellular-signal-regulated kinase (ERK) and its activated form in triple-negative
MDA-MB231 breast cancer cells after 18 h and up to 30 h of treatment, and to a lesser extent AKT
and phospho-AKT after 30 h and up to 48 h of treatment. Also, DNA methyltransferase 1 (DNMT1),
3b and, to a lesser extent, 3a, downstream ERK targets, were down-regulated already at 18 h with
an increase up to 48 h of exposure. Methylation-sensitive restriction arbitrarily-primed (MeSAP)
polymerase chain reaction (PCR) analysis confirmed the ability of JAHA to induce genome-wide
DNA hypomethylation at 48 h of exposure. Collective data suggest that JAHA, by down-regulating
phospho-ERK, impairs DNMT1 and 3b expression and ultimately DNA methylation extent, which
may be related to its cytotoxic effect on this cancer cytotype.
Keywords: histone deacetylase inhibitor; extracellular-signal-regulated kinase (ERK); AKT; DNA
methyltransferase (DNMT)
1. Introduction
N1-(ferrocenyl)-N8-hydroxyoctanediamide (JAHA) is an organometallic histone deacetylase
inhibitor (HDACi) analogue of suberoylanilide hydroxamic acid (SAHA), a US Food and Drug
Administration-approved anticancer drug [1]. It was designed such that the three-dimensional
spanning ferrocenyl group could replace the planar aryl “cap” group and act as a suitable bioisostere
(Figure 1). Since JAHA’s inception, a number of metal-based analogues, including rhenium and
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Figure 1. N1-(ferrocenyl)-N8-hydroxyoctanediamide (JAHA) (A) and suberoylanilide hydroxamic
acid (SAHA) (B) deacetylase inhibitors (HDACis).
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The ability of this compound to impair the growth of triple-negative, high malignant,
MDA-MB231 breast tumor cells (IC50 at 72 h = 8.45 µM) has already been reported [8]. In particular,
cell cycle perturbation, and early stage reactive oxygen species production followed by mitochondrial
dysfunction and autophagy inhibition accounted for the cytotoxic effect of exposure to JAHA at its
72h-IC50 concentration [8], with a noticeable absence of apoptotic promotion characteristic of SAHA
treatment on the same cells [9]. Here, we extended the investigation to the expression of AKT and
extracellular-signal-regulated kinase (ERK) signaling, which is known to play a crucial role in tumor
cell death/survival decision [10], in light of the documented ability of SAHA to deactivate both
factors in different cancer cell systems [11–13].
2. Results and Discussion
In a first set of assays, MDA-MB231 cells were exposed to a 8.45 µM concentration of JAHA
for 18, 30 and 48 h and Western blot analyses were performed to evaluate the accumulation of
total and activated (phosphorylated) AKT and ERK1 and ERK2 isoform proteins in control and
JAHA-exposed cells. As shown in Figure 2A, a decrease of total AKT down to 67.5% ˘ 4.8% and
54.7% ˘ 12% vs. controls was observed at 30 and 48 h of treatment with JAHA, respectively. The
pAKT/total AKT ratio did not change between treated and control samples in the time lapse of the
experiment. On the other hand, although exposure to 8.45 µM JAHA caused a significant decrease
of the accumulation of total ERK1/2 within 30 h of culture, followed by a prominent up-regulation,
a drastic reduction also in the amount of its activated forms (pERK) was observed at earlier times of
treatment (18 h = 38% ˘ 1.4%; 30 h = 29.1% ˘ 1.1% vs. controls), as shown in Figure 2B. Also, in this
case, the pERK/total ERK ratio did not change between treated and control samples in the time lapse
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(18 h  = 38% ± 1.4%;  30 h = 29.1% ± 1.1% vs.  controls),  as  shown  in Figure 2B. Also,  in  this  case,  
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the experiment,  suggesting  that  JAHA  treatment  impaired gene expression and not  the extent of 
protein activation. 
 
Figure  2.  Western  blot  analysis  of  AKT,  extracellular‐signal‐regulated  kinase  (ERK)  and  DNA 
methyltransferases  (DNMTs).  Histograms  showing  the  accumulation  of  (A)  AKT/pAKT;  
(B)  ERK/pERK;  and  (C)  DNMT1,  3a  and  3b  in  JAHA‐exposed  MDA‐MB231  cells  vs.  controls. 
Representative Western blots are  shown on  the  right. The  results are expressed as means ±  s.e.m 
(standard  error  of  the mean)  of  three  independent Western  blot  experiments.  *  p  <  0.05  (t‐test). 
Statistical analysis was performed with SigmaPlot 11.0 (Systat Software Inc., San Jose, CA, USA).  
Figure 2. Western blot analysis of AKT, extracellular-signal-regulated kinase (ERK) and
DNA methyltransferases (DNMTs). Histograms showing the accumulation of (A) AKT/pAKT;
(B) ERK/pERK; and (C) DNMT1, 3a and 3b in JAHA-exposed MDA-MB231 cells vs. controls.
Representative Western blots are shown on the right. The results are expressed as means ˘ s.e.m
(standard error of the mean) of three independent Western blot experiments. * p < 0.05 (t-test).
Statistical analysis was performed with SigmaPlot 11.0 (Systat Software Inc., San Jose, CA, USA).
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It is widely acknowledged that DNA methyltransferase 1 (DNMT1), DNMT3a and DNMT3b are
targets for signaling through ERK pathway and they are mainly involved in variants of the enzymatic
activity, i.e., maintenance (DNMT1) and de novo methylation (DNMT3a and 3b) [14–16]. We therefore
examined whether JAHA-triggered ERK1/2 deactivation could result in decreased methyltransferase
expression in MDA-MB231 cells. As shown in Figure 2C, the results obtained by Western blot
confirmed, at least in part, the hypothesis since JAHA treatment down-regulated DNMT1 and 3b
vs. controls at every time point examined. In particular, the decrease of DNMT1 expression level
was more prominent and steady (18 h = 24.4% ˘ 1.6%; 30 h = 29.1% ˘ 4.8%; 48 h = 29.2% ˘ 7.6%),
whereas that of DNMT3b peaked at 30 h from exposure (18 h = 40% ˘ 3%; 30 h = 28.3% ˘ 3.8%;
48 h = 57.8% ˘ 1.3%). On the other hand, JAHA was not effective in modifying the expression level
of DNMT3a at 18 and 30 h from exposure, whereas a late and less pronounced decrease (80% ˘ 3.9%)
could be observed after 48 h of treatment.
To confirm the observed down-regulation of DNMTs, the DNA isolated from cells grown for
18, 30 and 48 h either in control conditions or in the presence of 8.45 µM JAHA, was analyzed by
methylation-sensitive arbitrarily-primed polymerase chain reaction (MeSAP-PCR) [17,18] to unveil
changes induced by the drug on global methylation status of the genomic DNA. The obtained data
show that 48 h-treatment with JAHA was effective in modifying the global methylation pattern
of tumor cell DNA, as shown by the different number, intensity and size of the bands in the
matched control and exposed samples. In particular, as shown in Figure 3, the difference in
the electrophoretic patterns of single- and double-digested DNA puts in evidence an increase of
unmethylated CpG-containing sites related to a hypomethylated state of the genomic DNA after
exposure to JAHA. No statistically-significant difference was found at earlier times (not shown).
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Figure  3.  Analysis  of  genomewide  DNA  methylation  status.  Methylation‐sensitive  restriction  
arbitrarily‐primed (MeSAP) fingerprintings (A) and corresponding densitometry profiles (B,C) of the 
matched  single‐  (SDD  in  red profiles  in B,C) and double‐digested DNA  (DDD  in blue profiles  in 
B,C)  samples  from  control  (B)  and  JAHA‐treated  (C)  MDA‐MB231  cells  cultured  for  48  h.  The 
differences in the presence/absence of the peaks representing appeared/disappeared bands, or in peak 
heights corresponding to band intensification/attenuation (indicated by arrows in the profiles) were 
evaluated  to  compare  the  global  methylation  status.  The  results  are  representative  of  three 
independent experiments.  
Literature data report that HDAC1 is able to bind DNMT1 in vivo thereby forming a complex 
active  on  chromatin  remodeling  [19].  In  order  to  ascertain whether  JAHA  could  down‐regulate 
global DNA methylation  also by binding  to  this  complex  and  interfering with DNMT  action,  as 
suggested  for  the HDACi  trichostatin A  [20], we  performed  an  enzyme‐linked  immunosorbent 
assay  (ELISA)‐like  DNMT  inhibition  test  with  DNMT1‐containing  native  nuclear  extract  from 
MDA‐MB231  cells  in  the  presence  or  absence  of  JAHA.  The  obtained  results  indicated  that  the 
Figure 3. Analysis of genomewide DNA methylation status. ethylation-sensitive restriction
arbitrarily-primed ( e ) fingerprintings (A) and correspo ding densitometry profiles (B,C) of
the matched single- (SDD in (A), r d profiles in (B,C)) and (DD in (A), blue profiles in (B,C))
sample from control (B) and JAHA-treated (C) MDA-MB231 cells cultured for 48 h. The differences
in th pr e ce/absence of the peaks representing appeared/ isap eared or in peak
heights corresponding band intensification/attenuatio (indicated by arrows in th profiles)
w re evaluated t compare the global methylation status. The re ults a representative of three
independent experiments.
Literature data report that HDAC1 is able to bind DNMT1 in vivo thereby forming a complex
active on chromatin remodeling [19]. In order to ascertain whether JAHA could down-regulate
global DNA methylation also by binding to this complex and interfering with DNMT action, as
suggested for the HDACi trichostatin A [20], we performed an enzyme-linked immunosorbent assay
(ELISA)-like DNMT inhibition test with DNMT1-containing native nuclear extract from MDA-MB231
cells in the presence or absence of JAHA. The obtained results indicated that the enzymatic activity
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was comparable for both control and JAHA-containing samples (Figure 4), thereby excluding a direct
interaction of the drug.
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and Librizzi et al.  [8] with minor modifications. Essentially,  lysates  of  control  and  JAHA‐treated 
cells  were  submitted  to  10%  sodium  dodecyl  sulphate‐polyacrylamide  gel  electrophoresis  
(SDS‐PAGE) with  subsequent  protein  transfer  onto Hybond‐ECL  nitrocellulose membranes  (GE 
Healthcare,  Piscataway,  NJ,  USA)  using  a  Novablot  semidry  apparatus  (Amersham  Pharmacia 
Biotech,  Piscataway, NJ, USA).  Immunorevelation was  performed with  either  rabbit  polyclonal  
anti‐Erk1/2 antibody (ab17,942, 1:500, Abcam, Cambridge, UK), anti‐AKT antibody (9272, 1:750, Cell 
Signaling, Danvers, MA, USA),  anti‐p‐Erk1/2  antibody  (9101,  1:750,  Cell  Signaling),  anti‐p‐AKT 
antibody (sc‐7985‐R, 1:750, Santa Cruz Biotechnology, Santa Cruz, CA, USA,) anti‐DNMT1 antibody 
(SAB2106406, 1:250, Sigma), anti‐DNMT3a antibody (orb228930, 1:500, Biorbyt, Cambridge, UK) or 
anti‐DNMT3b  antibody  (Q‐25)  (sc‐130,740,  1:200,  Santa  Cruz  Biotechnology),  and  anti‐actin 






Figure 4. Enzyme-linked immunosorbent assay (ELISA) of DNMT activity. Histogram showing the
methyltransferase activity of nuclear extracts of MDA-MB231 cells in control and JAHA-exposed
conditions. The results are expressed as means˘ s.e.m. of three independent ELISA assays. Statistical
analysis was performed with SigmaPlot 11.0 (Systat Software Inc.). OD: Optical density.
3. Experimental Section
3.1. ell ulture and J Treat ent
- B231 breast tu or cells were maintained in RPMI 1640 medium plus 10% foetal
calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2.5 mg/L amphotericin B
(Life Technologies, Carlsbad, CA, USA), at 37 ˝C in a 5% CO2 atmosphere. The cells were detached
from flasks with 0.05% trypsin-EDTA (ethylenediaminetetraacetic acid), counted, and plated at the
necessary density for treatment after achieving 60%–80% confluency. JAHA was synthesized as
reported by Spencer et al. [1] and dissolved at 6.5 mM concentration in dimethyl sulfoxide (DMSO)
as stock solution.
3.2. Western Blot
Control and JAHA-tr ated MDA-MB231 c lls were trypsinized, w shed in Phosphate buffered
saline (P S), pelleted by centrifugati n and lysed in a lysis buffer containing 7 M urea, 2% CHAPS,
1% IPG Buffer, 10 mM dithiothreitol (DTT), 1 mM phenylmethyl ulfonyl fluoride (PMSF) and
protease and phosphatases inhibitor cocktail (Sigma, S . Louis, MO, USA). The lysates were
centrifuged at 1000 rpm for 1 min at 4 ˝C. Protein concentrations were estimated by Bradford
ssay (Bio-Rad, Hercules, CA, USA). Ele trophoretic an ysis and immunoblots were perform
according to Chiarelli et al. [21] and Librizzi et al. [8] wit minor modifications. Essentially, lysate
of control and JAHA-treated cells w re submitted to 10% s dium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) with ubsequent pr tein transfer onto Hybond-ECL nitrocellulose
membranes (GE Healthcare, Piscataway, NJ, USA) using a Novablot semidry appa tus (Amersham
Pharmacia Biotech, Piscataway, NJ, USA). Immunorev lation was performed with either rabbit
polyclo al anti-E k1/2 antibody (ab17,942, 1:500, Abcam, Cambridge, UK), anti-AKT antibody
(9272, 1:750, Cell Signaling, Danvers, MA, USA), i-p-Erk1/2 antibody (9101, 1:750, Cell
Signaling), anti-p-AKT antibody (sc-7985-R, 1:750, Santa Cruz Biotechnology, Santa Cruz, CA,
USA,) anti-DNMT1 antibody (SAB2 06406, 1:250, Sigm ), anti-DNMT3a antibody (orb228930,
1:500, Biorbyt, Cambridge, UK or anti-DNMT3b ntibody (Q-25) (sc-130,740, 1:200, Santa Cruz
Biotechnology), an anti-actin ntibody (A5060, 1:500, Sigma) the latter as a loading control. The
secondary an ibody was a hor er dish peroxidase-conjugated anti-rabbit IgG antibody (W4011,
Promega, Madison, WI, USA, 1:25,000). Protein bands were visualized using a Chemidoc XRS
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(Bio-Rad, Hercules, CA, USA) and the ImmunStar Western C Substrate Kit (Bio-Rad). The intensities
of the bands of interest, evaluated with Quantity One v.4.6.6 software (Bio-Rad), were normalized for
those of actin.
3.3. Methylation-Sensitive Arbitrarily-Primed (MeSAP)-PCR
The genomic DNA was purified from control and treated cells with the PureLinkTM Genomic
DNA Kit (Life Technologies) according to manufacturers’ instructions. Two micrograms of the
DNA samples were digested with 10 U of AfaI restriction endonuclease (Life Technologies) to
generate single digested DNA (SDD) samples. The cleavage site of the enzyme is (GT*AC). Half
of SDD were further treated with 5 U of HpaII (Life Technologies), a methylation-sensitive restriction
endonuclease unable to cut DNA if methylated cytosine is present in its recognition site (CG*GG), to
generate double digested DNA samples (DDD). SDD and DDD samples were separately amplified
by arbitrarily-primed PCR using two subsequent amplification cycles. In the first low stringency
cycle, a permissive annealing temperature and a high salt and primer concentration were set to allow
annealing of the arbitrary primer to the best matches in the template with the highest preference
for all the genomic CpG sites since it is provided with a 31 tail complementary to these sites.
The first PCR cycle was performed in the presence of 500 ng of DNA, a 21-mer arbitrary primer
(51-AACTGAAGCAGTGGCCTCGCG-31) and recombinant Taq DNA polymerase (Life Technologies),
and cycle profile was 94 ˝C for 5 min followed by four cycles at 94 ˝C for 30 s, 40 ˝C for 60 s and 72 ˝C
for 90 s The profile of the second high stringency cycle, performed just after the first one, was 94 ˝C
for 1 min, followed by four cycles at 60 ˝C for 1 min and 72 ˝C for 2 min. The amplified DNA was
resolved by non-denaturating 6% acrylamide-bisacrylamide (29:1 ratio) gel electrophoresis, stained
with Gel Red nucleic acid gel stain (Biotium, Hayward, CA, USA), and analysed with SigmaGel v.1.0
image analysis software (SPSS, Chicago, IL, USA).
3.4. ELISA Assay
MDA-MB231 cells were grown in control conditions as already reported, and collected by
scraping and centrifugation of the suspension. The cell pellet was re-suspended in a hypotonic
buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2) containing 0.5% NP-40 detergent and
protease inhibitor cocktail, and the nuclear proteins obtained after centrifugation of the homogenate
for 10 min at 3000 rpm in the cold. The nuclear pellet was then dissolved in an extraction
buffer (100 mM Tris, pH 7.4, 2 mM Na3VO4, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10%
glycerol, 1 mM EGTA, 1 mM NaF, 0.5% deoxycholate, 20 mM Na4P2O7) and the nuclear proteins
obtained as a supernatant after centrifugation for 30 min at 14,000 ˆg in the cold and stored in
aliquots at ´80 ˝C after quantitation via Bradford assay. The DNMT-containing native nuclear
extract was submitted to an ELISA-like DNMT inhibition test (EpiQuik™, Farmingdale, NY, USA,
DNA Methyltransferase Activity/Inhibition Assay Kit, Epigentek, Farmingdale, NY, USA) according
to manufacturer’s instructions, in the presence or absence of JAHA to check whether the drug
could directly bind the enzymes and interfere with their activity. Essentially, in this kit a unique
cytosine-rich DNA substrate coated on the strip wells can be methylated by DNMT enzymes
transferring a methyl group to cytosine from Adomet. The methylated DNA can be recognized
with an anti-5-methylcytosine antibody and its amount quantified colorimetrically through an ELISA
reaction. DNMT activity (optical density (OD) (mg/h)) was calculated according to the following
formula: ((sample OD ´ blank OD)/(sample protein ˆ incubation time)) ˆ 1000.
4. Conclusions
In conclusion, our data demonstrate that, opposed to SAHA, JAHA action on MDA-MB231
cells is addressed towards the sole deactivation of pERK1/2, leaving pAKT levels unaltered. On
the other hand, the time-dependent variations in ERK1/2 level of phosphorylation are in line with
those reported for SAHA-treated MDA-MB231 cells and attributable to the depletion of upstream
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molecules before 48 h of exposure [22]. Accumulation of total AKT appears to decrease with time
whereas that of total ERK1/2 shows a U-shaped pattern with up-regulation at 48 h of exposure.
This represents an additional aspect of diversity between JAHA and SAHA, whose lack of effect
especially on total ERK content has been described in different cell model systems [11,12] and its
biological implication remains to be determined. Our results show that JAHA inhibits mainly the
accumulation of DNMT1 and DNMT3b and methyltransferase activity thereby influencing gene
expression also in a manner alternative to that of histone acetylation. It is known that both DNMTs
are responsible of the hypermethylation/silencing of tumor suppressor genes [23,24] and therefore it
is conceivable that the DNA demethylation following JAHA treatment results in the rearrangement
of the molecular landscape of transcriptional regulation and restoration of gene expression. This
can ultimately account, at least in part, for the cytotoxic effect of the drug on this cancer cytotype.
Characterization of the molecular basis of the different effect exerted by JAHA on DNMT3a with
respect to DNMT1 and DNMT3b, and identification of the specific gene promoters targeted by the
JAHA-triggered demethylation events will deserve future and more detailed investigation. These
results add to a growing number of publications highlighting the use of metal-based HDACis as
effective probes in cancer [5].
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